RSVP—the Reimbursement Solutions, Verification, and Payment HELPline—is a reimbursement support service
and patient assistance program designed to help patients gain access to the Pfizer medicines they need.
The program assists patients with reimbursement support, appeals process information, and—in some cases—
finding alternate funding assistance, while helping patients understand their coverage options. RSVP is
staffed by knowledgeable representatives who are available to help patients.
WHAT IS RSVP?
RSVP helps patients obtain specific Pfizer medicines, including Zyvox® (linezolid).
HOW TO CONTACT RSVP
By phone
Contact RSVP at 1-888-327-RSVP (7787) to speak to a live operator in English or Spanish (M-F, 9:00 AM - 8:00 PM Eastern Time).
By fax
You can also contact RSVP by fax
at 1-888-773-0121.
By mail
Send correspondence to:
Pfizer RSVP
PO Box 220574
Charlotte, NC 28222-0574
FOR INSURED PATIENTS
RSVP offers reimbursement support services
An RSVP representative will help patients and their health care professionals understand coverage options and provide reimbursement support services for the Pfizer medicines available through this program. They'll research and verify benefits, explain coverage options and policies, as well as investigate and explain the prior authorization process.
RSVP offers appeals process information
If a claim is underpaid or denied, RSVP will investigate and explain the appeals process.
RSVP offers alternate funding assistance
RSVP can help patients by checking their eligibility for various alternate funding sources. In certain cases, patients can make use of supplemental assistance, such as state pharmaceutical assistance programs (SPAPs), Medicaid, Medicare Part D, low-income subsidies, and charitable foundations.
RSVP offers Hardship Exceptions
Patients who demonstrate significant financial hardship (eg. cannot afford their co-insurance or have been denied coverage) can apply for a Hardship Exception through the RSVP program. If eligible, patients can access Pfizer medicines for free. Eligibility for financial exceptions varies by product. An RSVP representative will help determine a patient's eligibility for a Hardship Exception.
FOR UNINSURED PATIENTS
RSVP offers patient assistance
Through the RSVP patient assistance program, eligible patients may be able to get Pfizer medicines for free. An RSVP representative will help determine the patients' eligibility.
To be eligible, patients must:
- Have no prescription coverage
- Meet specific income guidelines, adjusted for family size
- Reside in the United States, Purto Rico, or US Virgin Islands and be treated by a US-licensed physician*
RSVP will then arrange for an initial supply of the necessary medicine to be sent to the patient's home or physician's office. If Zyvox® is needed, It can be made available immediately through a local pharmacy once eligibility has been confirmed. Re-enrollment is required after 12 months if the patient is still eligible.
HOW DOES RSVP WORK?
For assistance, please call 1-888-327-7787. A Pfizer RSVP representative will determine a patient's eligibility as well as help patients through the enrollment process, verification, and fulfillment.
Be ready to provide:
- Name, address, and phone number of prescribing physician or facility
- Physician's NPI (National Provider Identifier)
- Taxpayer ID number of facility
- Patient information, including Social Security Number+
- Patient insurance information, including policy ID number and group number
- Patient treatment, diagnosis, and supporting documentation
Be sure to be in compliance with HIPAA privacy regulations.
*For Puerto Rico, must be treated by a Puerto Rico-licensed physician.
+Social Security number required for insured patients if needed to verify benefits.
ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms. ZYVOX is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.
Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae.
Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. ZYVOX has not been studied in the treatment of decubitus ulcers.
ZYVOX use is contraindicated in patients with known hypersensitivity to linezolid or any of the other product components.
ZYVOX should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within 2 weeks of taking any such product.
Unless patients are monitored for potential increases in blood pressure, ZYVOX should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following: directly and indirectly acting sympathomimetic, vasopressive, and dopaminergic agents.
Unless patients are carefully observed for signs and/or symptoms of serotonin syndrome, ZYVOX should not be administered to patients with carcinoid syndrome and/or patients taking any of the following medications: serotonin reuptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists, meperidine, or buspirone.
Spontaneous reports of serotonin syndrome have been reported with the coadministration of ZYVOX and serotonergic agents. If signs or symptoms of serotonin syndrome, such as cognitive dysfunction, hyperpyrexia, hyperreflexia, and incoordination occur, discontinuation of one or both agents should be considered.
Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving ZYVOX. In cases where the outcome is known, when ZYVOX was discontinued, the affected hematologic parameters returned to pretreatment levels. Complete blood counts should be monitored weekly, particularly in patients who receive ZYVOX for longer than 2 weeks.
ZYVOX is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections.
ZYVOX has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.
Clostridium difficile associated diarrhea has been reported with use of nearly all antibacterial agents, including ZYVOX, and may range in severity from mild diarrhea to fatal colitis.
Lactic acidosis has been reported with the use of ZYVOX. Patients receiving ZYVOX who develop recurrent nausea, vomiting, unexplained acidosis, or a low bicarbonate level should receive immediate medical evaluation.
Peripheral and optic neuropathy have been reported primarily in patients treated with ZYVOX for longer than the maximum recommended duration of 28 days. If patients experience symptoms of visual impairment, prompt ophthalmic evaluation is recommended.
Convulsions have been reported in patients treated with ZYVOX. In some of these cases, a history of seizures or risk factors for seizures was reported.
The most commonly reported adverse events in adults across phase 3 clinical trials were diarrhea, nausea, and headache.
ZYVOX Indications
ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms. ZYVOX is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.
Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae.
Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. ZYVOX has not been studied in the treatment of decubitus ulcers.
Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia.
Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes.
Community-acquired pneumonia caused by Streptococcus pneumoniae, including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Important Safety Information
ZYVOX use is contraindicated in patients with known hypersensitivity to linezolid or any of the other product components.
ZYVOX should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within 2 weeks of taking any such product.
Unless patients are monitored for potential increases in blood pressure, ZYVOX should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following: directly and indirectly acting sympathomimetic, vasopressive, and dopaminergic agents.
Unless patients are carefully observed for signs and/or symptoms of serotonin syndrome, ZYVOX should not be administered to patients with carcinoid syndrome and/or patients taking any of the following medications: serotonin reuptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists, meperidine, or buspirone.
Spontaneous reports of serotonin syndrome have been reported with the coadministration of ZYVOX and serotonergic agents. If signs or symptoms of serotonin syndrome, such as cognitive dysfunction, hyperpyrexia, hyperreflexia, and incoordination occur, discontinuation of one or both agents should be considered.
Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving ZYVOX. In cases where the outcome is known, when ZYVOX was discontinued, the affected hematologic parameters returned to pretreatment levels. Complete blood counts should be monitored weekly, particularly in patients who receive ZYVOX for longer than 2 weeks.
ZYVOX is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections.
ZYVOX has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.
Clostridium difficile associated diarrhea has been reported with use of nearly all antibacterial agents, including ZYVOX, and may range in severity from mild diarrhea to fatal colitis.
Lactic acidosis has been reported with the use of ZYVOX. Patients receiving ZYVOX who develop recurrent nausea, vomiting, unexplained acidosis, or a low bicarbonate level should receive immediate medical evaluation.
Peripheral and optic neuropathy have been reported primarily in patients treated with ZYVOX for longer than the maximum recommended duration of 28 days. If patients experience symptoms of visual impairment, prompt ophthalmic evaluation is recommended.
Convulsions have been reported in patients treated with ZYVOX. In some of these cases, a history of seizures or risk factors for seizures was reported.
The most commonly reported adverse events in adults across phase 3 clinical trials were diarrhea, nausea, and headache.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.
